Literature DB >> 8879970

Anticonvulsant-induced psychiatric disorders. The role of forced normalisation.

M R Trimble1.   

Abstract

With the introduction of several new anticonvulsant drugs into clinical practice in recent years, renewed attention has been paid to treatment-emergent effects, especially behavioural syndromes. In this review, the more severe psychiatric syndromes that may be associated with anticonvulsants are discussed, especially personality disorders, affective syndromes and psychoses. The important concept of forced normalisation is discussed, and its clinical counterpart, alternative psychosis. Affective disorders and psychoses have been described as associated with most of the new anticonvulsant agents, and they are often seen in a setting in which previously intractable patients suddenly become seizure free. Other cases may relate to intoxication, the precipitation of a status epilepticus, or ensue as part of the background frequency of those syndromes that are seen in epilepsy irrespective of medication.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8879970     DOI: 10.2165/00002018-199615030-00001

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  29 in total

1.  [Psychiatric and psychologic effects of ethosuximide treatment of epileptics].

Authors:  J Roger; H Grangeon; J Gueyj; H Lob
Journal:  Encephale       Date:  1968 Sep-Oct       Impact factor: 1.291

2.  Psychotic episodes in Zarondan treatment. Effects and side-effects in 105 patients.

Authors:  M Fischer; G Korskjaer; E Pedersen
Journal:  Epilepsia       Date:  1965-12       Impact factor: 5.864

3.  Hypomania induced by gabapentin.

Authors:  C Short; L Cooke
Journal:  Br J Psychiatry       Date:  1995-05       Impact factor: 9.319

4.  Anticonvulsant drugs alter plasma tryptophan concentrations in epileptic patients: implications for antiepileptic action and mental function.

Authors:  J A Pratt; P Jenner; A L Johnson; S D Shorvon; E H Reynolds
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-10       Impact factor: 10.154

5.  Manic state with carbamazepine therapy of seizures.

Authors:  M E Drake; W T Peruzzi
Journal:  J Natl Med Assoc       Date:  1986-11       Impact factor: 1.798

6.  The Bear-Fedio personality inventory and temporal lobe epilepsy.

Authors:  E Rodin; S Schmaltz
Journal:  Neurology       Date:  1984-05       Impact factor: 9.910

7.  Phenobarbital treatment and major depressive disorder in children with epilepsy.

Authors:  D A Brent; P K Crumrine; R R Varma; M Allan; C Allman
Journal:  Pediatrics       Date:  1987-12       Impact factor: 7.124

8.  Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0.5 Clinical Trial Group.

Authors:  F Matsuo; D Bergen; E Faught; J A Messenheimer; A T Dren; G D Rudd; C G Lineberry
Journal:  Neurology       Date:  1993-11       Impact factor: 9.910

9.  Vigabatrin and psychosis.

Authors:  J W Sander; Y M Hart; M R Trimble; S D Shorvon
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-05       Impact factor: 10.154

10.  A comparative study of the cognitive effects of phenytoin and carbamazepine in new referrals with epilepsy.

Authors:  D G Andrewes; J G Bullen; L Tomlinson; R D Elwes; E H Reynolds
Journal:  Epilepsia       Date:  1986 Mar-Apr       Impact factor: 5.864

View more
  3 in total

Review 1.  Interventions for psychotic symptoms concomitant with epilepsy.

Authors:  Saeed Farooq; Akhtar Sherin
Journal:  Cochrane Database Syst Rev       Date:  2015-12-21

2.  Rats bred for susceptibility to depression-like phenotypes have higher kainic acid-induced seizure mortality than their depression-resistant counterparts.

Authors:  Kroshona Tabb; Katherine A Boss-Williams; Jay M Weiss; David Weinshenker
Journal:  Epilepsy Res       Date:  2007-04-02       Impact factor: 3.045

Review 3.  Behavioural effects of the new anticonvulsants.

Authors:  F M Besag
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.